Close

Anti-CD19 (1D3) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-YF421)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of B-Cell Malignancies.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD19
  • Targeting Cell Type
  • T Cell
  • Targeting Diseases
  • B-Cell Malignancies
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 1D3
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CD19
  • Synonyms
  • CD19;CD19; CD19 Molecule; CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; B-Lymphocyte Antigen CD19; CVID3; B4;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FuncS

Fig.1 Flow cytometry analysis of CD3+ or CD19+ cells in mice treated with anti-CD19 (1D3) CAR-T or anti-FITC CAR-T with anti-CD19 (1D3)-FITC switch.

CAR Construction : 1D3 scfv-CD28-CD3ζ Latest CAR Construction

Fig.1 Flow cytometry analysis of CD3+ or CD19+ cells in mice treated with anti-CD19 (1D3) CAR-T or anti-FITC CAR-T with anti-CD19 (1D3)-FITC switch.

C57BL/6 mice were preconditioned with cyclophosphamide (150 mg/kg) on day 1, and received 6 × 106 syngeneic anti-CD19 (ID3) CAR or anti-FITC CAR-T cells by tail-vein injections the next day. Daily treatments with anti-mouse CD19 (1D3)-FITC switch at 1 mg/kg were initiated the same day as CAR-T-cell infusions for a total of 10 injections (days 2-11).

Ma, J. S., Kim, J. Y., Kazane, S. A., Choi, S. H., Yun, H. Y., Kim, M. S., ... & Cao, Y. (2016). Versatile strategy for controlling the specificity and activity of engineered T cells. Proceedings of the National Academy of Sciences, 113(4), E450-E458.

Complete CAR data FuncS

Fig.2 Quantified analysis of CD19+ cells in mice treated with anti-CD19 (1D3) CAR-T or anti-FITC CAR-T with anti-CD19 (1D3)-FITC switch.

CAR Construction : 1D3 scfv-CD28-CD3ζ Latest CAR Construction

Fig.2 Quantified analysis of CD19+ cells in mice treated with anti-CD19 (1D3) CAR-T or anti-FITC CAR-T with anti-CD19 (1D3)-FITC switch.

Graphical representation of CD19+ cells quantified from B. Results are displayed as an average of five to six mice.

Ma, J. S., Kim, J. Y., Kazane, S. A., Choi, S. H., Yun, H. Y., Kim, M. S., ... & Cao, Y. (2016). Versatile strategy for controlling the specificity and activity of engineered T cells. Proceedings of the National Academy of Sciences, 113(4), E450-E458.

Complete CAR data FuncS

Fig.3 Anti-CD19–CAR-expressing T cells produce IL-2 and proliferate in response to CD19.

CAR Construction : 1D3 scfv-CD28-CD3ζ Latest CAR Construction

Fig.3 Anti-CD19–CAR-expressing T cells produce IL-2 and proliferate in response to CD19.

1D3-28Z.1-3-transduced T cells, 1D3-28Z-transduced T cells, or SP6-28Z.1-3-transduced T cells were cultured overnight alone or with the indicated target cells, and an IL-2 ELISA was performed.

Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, The Journal of the American Society of Hematology, 116(19), 3875-3886.

Complete CAR data FuncS

Fig.4 Functional anti-CD19–CAR-transduced T cells were detected in mice after adoptive transfer.

CAR Construction : 1D3 scfv-CD28-CD3ζ Latest CAR Construction

Fig.4 Functional anti-CD19–CAR-transduced T cells were detected in mice after adoptive transfer.

Mice received 5 Gy of TBI and injected intraperitoneally with 38c13 lymphoma cells, then received CAR-T cells . Eight days after the T-cell transfer, the mice were killed and splenocytes were stained with mouse anti-rat Fab antibodies to detect CAR-transduced cells.

Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, The Journal of the American Society of Hematology, 116(19), 3875-3886.

Complete CAR data FuncS

Fig.5 Functional anti-CD19–CAR-transduced T cells were detected in mice after adoptive transfer.

CAR Construction : 1D3 scfv-CD28-CD3ζ Latest CAR Construction

Fig.5 Functional anti-CD19–CAR-transduced T cells were detected in mice after adoptive transfer.

Mean absolute numbers of CAR-expressing CD3+CD8+ splenocytes in mice that received either 1D3-28Z.1-3-transduced T cells or 1D3-28Z-transduced T cells.

Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, The Journal of the American Society of Hematology, 116(19), 3875-3886.

Complete CAR data FuncS

Fig.6 Functional anti-CD19–CAR-transduced T cells were detected in mice after adoptive transfer.

CAR Construction : 1D3 scfv-CD28-CD3ζ Latest CAR Construction

Fig.6 Functional anti-CD19–CAR-transduced T cells were detected in mice after adoptive transfer.

Mean absolute numbers of CAR-expressing CD3+CD4+ splenocytes in mice that received either 1D3-28Z.1-3-transduced T cells or 1D3-28Z-transduced T cells.

Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, The Journal of the American Society of Hematology, 116(19), 3875-3886.

Complete CAR data FuncS

Fig.7 Functional anti-CD19–CAR-transduced T cells were detected in mice after adoptive transfer.

CAR Construction : 1D3 scfv-CD28-CD3ζ Latest CAR Construction

Fig.7 Functional anti-CD19–CAR-transduced T cells were detected in mice after adoptive transfer.

Eight days after T-cell transfer, the mice were killed, and splenocytes were cultured with 38c13, CD19-K562, or NGFR-K562. 38c13 and CD19-K562 were CD19+. NGFR-K562 was CD19-. Intracellular cytokine staining was performed for IFN-γ. The numbers on the plots represent the percentage of CD3+ cells.

Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, The Journal of the American Society of Hematology, 116(19), 3875-3886.

Complete CAR data FuncS

Fig.8 Anti-CD19–CAR-transduced T cells eradicated large lymphoma masses

CAR Construction : 1D3 scfv-CD28-CD3ζ Latest CAR Construction

Fig.8 Anti-CD19–CAR-transduced T cells eradicated large lymphoma masses

Mice received 5 Gy of TBI and injected intraperitoneally with 38c13 lymphoma cells, then received CAR-T cells. The mean tumor sizes of each group are shown.

Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, The Journal of the American Society of Hematology, 116(19), 3875-3886.

Complete CAR data FuncS

Fig.9 Anti-CD19–CAR-transduced T cells eradicated large lymphoma masses

CAR Construction : 1D3 scfv-CD28-CD3ζ Latest CAR Construction

Fig.9 Anti-CD19–CAR-transduced T cells eradicated large lymphoma masses

The survival of the same groups of mice described in vivo assay is shown.

Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, The Journal of the American Society of Hematology, 116(19), 3875-3886.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD19 (1D3) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-YF421). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.